Oak Brook, IL - The April edition of SLAS Technology features the cover article "Therapeutic Potential of Reactive Oxygen Species: State of the Art and Recent Advances" by Valeria Graceffa, Ph.D. (Institute of Technology Sligo, Sligo, Ireland).
The cover article explores the therapeutic potential of reactive oxygen species (ROS) including applications ranging from wound healing and hair growth enhancement, to cancer treatment, stem cell differentiation and tissue engineering. At low concentrations, ROS can be utilized as inexpensive and convenient inducers of tissue regeneration, triggering stem cell differentiation and enhancing collagen synthesis. Recent cancer studies have represented ROS as the 'Achilles Heels' of cancers given their high basal levels, leaving tumoral cells unable to sufficiently handle the additional source of oxidative stress. Because of this, higher doses of ROS are used for targeted killing of tumor cells. Lack of understanding of the technicalities between anabolic and cytotoxic effects means limited ROS clinical translation opportunities. While there is ample potential for the use of ROS, new strategies to control temporal pattern of ROS release have yet to be developed.
The April issue of SLAS Technology includes six articles of original research including:
Other articles include:
###
Access to April's SLAS Technology issue is available at https://journals.sagepub.com/toc/jlad/26/2 . For more information about SLAS and its journals, visit http://www.slas.org/journals .
SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.
SLAS Discovery: Advancing the Science of Drug Discovery, 2019 Impact Factor 2.195. Editor-in-Chief Robert M. Campbell, Ph.D., Twentyeight-Seven Therapeutics, Boston, MA (USA).
SLAS Technology : Translating Life Sciences Innovation, 2019 Impact Factor 2.174. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore).
SLAS TECHNOLOGY